ReviewActa dermato-venereologica2020
Counting the Burden: Atopic Dermatitis and Health-related Quality of Life.
Review in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06324695 (DEVISE - Development and Evaluation of an Online Intervention to Reduce Self-stigma in People With Visible Chronic Skin Diseases), which is not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DEVISE - Development and Evaluation of an Online Intervention to Reduce Self-stigma in People With Visible Chronic Skin Diseases: a Randomized Controlled Trial
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials.Inflammopharmacology · 2026Pooled it
- Mapping the relationship between atopic dermatitis and gut microbiota: a bibliometric analysis, 2014-2023.Frontiers in microbiology · 2024Pooled it
- Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.BMC medicine · 2026Trial
- Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Acceptance and Commitment Therapy Eczema Management Program for Children With Eczema: A Pilot Randomised Controlled Trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Trial
- Article
- Impact of Chronic Spontaneous Urticaria on Major Life-Changing Decisions: An Exploratory Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Early-mid gestation as a critical predictive window for infantile atopic dermatitis: A longitudinal multi-matrix metabolomic study.The World Allergy Organization journal · 2026Article
- An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.Molecular medicine (Cambridge, Mass.) · 2026Review
- Clinical Dose-Response of Inflammation Formula Number 1 Granules Versus Traditional Decoction in the Treatment of Patients With Mild to Moderate Atopic Dermatitis: Protocol for a Multicenter Randomized Controlled Trial.JMIR research protocols · 2026Article
- Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial.Life (Basel, Switzerland) · 2026Article
- Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.Italian journal of pediatrics · 2026Article
- Atopic Dermatitis in Denmark: Regional Variation.Acta dermato-venereologica · 2026Article
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Clinical and Functional Determinants of Caregiver Burden in Elderly Patients with Atopic Dermatitis: A Multicentre Cross-Sectional Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Parental perspective of the impact of atopic dermatitis on the quality of life in children in Saudi Arabia: A cross-sectional study.Journal of family medicine and primary care · 2026Article
- New insights in the burden of atopic dermatitis: How holistic care also considers socio-economics.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis is the most prevalent chronic inflammatory skin condition globally. The burden of atopic dermatitis on children and adults is extensive and there is also significant impact on the lives of patient caregivers and family members. It is important to be able to measure this impact to inform clinical decisions and to plan appropriate patient and carer support. The current impact of atopic dermatitis on children and adults can be measured using several different quality of life questionnaires: the most frequently used are the Dermatology Quality of Life (DLQI), Children's Dermatology Quality of Life and Infants Dermatology Quality of Life. The impact on partners and family can be measured using several atopic dermatitis specific questionnaires or the Family DLQI or the generic Family Reported Outcome Measure, FROM-16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.